BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19040532)

  • 1. Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer.
    Jhavar S; Brewer D; Edwards S; Kote-Jarai Z; Attard G; Clark J; Flohr P; Christmas T; Thompson A; Parker M; Shepherd C; Stenman UH; Marchbank T; Playford RJ; Woodhouse C; Ogden C; Fisher C; Kovacs G; Corbishley C; Jameson C; Norman A; De-Bono J; Bjartell A; Eeles R; Cooper CS
    BJU Int; 2009 May; 103(9):1256-69. PubMed ID: 19040532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.
    Tomlins SA; Alshalalfa M; Davicioni E; Erho N; Yousefi K; Zhao S; Haddad Z; Den RB; Dicker AP; Trock BJ; DeMarzo AM; Ross AE; Schaeffer EM; Klein EA; Magi-Galluzzi C; Karnes RJ; Jenkins RB; Feng FY
    Eur Urol; 2015 Oct; 68(4):555-67. PubMed ID: 25964175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer.
    Setlur SR; Mertz KD; Rubin MA
    BJU Int; 2009 May; 103(9):1293; author reply 1293. PubMed ID: 19402829
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.
    Ateeq B; Kunju LP; Carskadon SL; Pandey SK; Singh G; Pradeep I; Tandon V; Singhai A; Goel A; Amit S; Agarwal A; Dinda AK; Seth A; Tsodikov A; Chinnaiyan AM; Palanisamy N
    Prostate; 2015 Jul; 75(10):1051-62. PubMed ID: 25809148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.
    Grupp K; Diebel F; Sirma H; Simon R; Breitmeyer K; Steurer S; Hube-Magg C; Prien K; Pham T; Weigand P; Michl U; Heinzer H; Kluth M; Minner S; Tsourlakis MC; Izbicki JR; Sauter G; Schlomm T; Wilczak W
    Prostate; 2013 Nov; 73(15):1690-8. PubMed ID: 23843146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complex patterns of ETS gene alteration arise during cancer development in the human prostate.
    Clark J; Attard G; Jhavar S; Flohr P; Reid A; De-Bono J; Eeles R; Scardino P; Cuzick J; Fisher G; Parker MD; Foster CS; Berney D; Kovacs G; Cooper CS
    Oncogene; 2008 Mar; 27(14):1993-2003. PubMed ID: 17922029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.
    Bhalla R; Kunju LP; Tomlins SA; Christopherson K; Cortez C; Carskadon S; Siddiqui J; Park K; Mosquera JM; Pestano GA; Rubin MA; Chinnaiyan AM; Palanisamy N
    Mod Pathol; 2013 Jun; 26(6):835-48. PubMed ID: 23348902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer.
    Smit FP; Salagierski M; Jannink S; Schalken JA
    BJU Int; 2013 May; 111(5):836-42. PubMed ID: 23578236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y.
    Massoner P; Kugler KG; Unterberger K; Kuner R; Mueller LA; Fälth M; Schäfer G; Seifarth C; Ecker S; Verdorfer I; Graber A; Sültmann H; Klocker H
    PLoS One; 2013; 8(2):e55207. PubMed ID: 23390522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer.
    Bismar TA; Yoshimoto M; Duan Q; Liu S; Sircar K; Squire JA
    Histopathology; 2012 Mar; 60(4):645-52. PubMed ID: 22260502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue.
    Lu Z; Williamson SR; Carskadon S; Arachchige PD; Dhamdhere G; Schultz DS; Stricker H; Peabody JO; Jeong W; Chitale DA; Bismar TA; Rogers CG; Menon M; Gupta NS; Palanisamy N
    Prostate; 2020 Jan; 80(1):38-50. PubMed ID: 31584209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.
    Brooks JD; Wei W; Hawley S; Auman H; Newcomb L; Boyer H; Fazli L; Simko J; Hurtado-Coll A; Troyer DA; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Feng Z; McKenney JK
    PLoS One; 2015; 10(7):e0132343. PubMed ID: 26172920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
    Dhani NC; Emmenegger U; Adams L; Jongstra J; Tannock IF; Sridhar SS; Knox JJ; Day JR; Groskopf J; Joshua AM
    BJU Int; 2012 Sep; 110(6):840-5. PubMed ID: 22313860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of SPINK1 in ETS rearrangement-negative prostate cancers.
    Tomlins SA; Rhodes DR; Yu J; Varambally S; Mehra R; Perner S; Demichelis F; Helgeson BE; Laxman B; Morris DS; Cao Q; Cao X; Andrén O; Fall K; Johnson L; Wei JT; Shah RB; Al-Ahmadie H; Eastham JA; Eggener SE; Fine SW; Hotakainen K; Stenman UH; Tsodikov A; Gerald WL; Lilja H; Reuter VE; Kantoff PW; Scardino PT; Rubin MA; Bjartell AS; Chinnaiyan AM
    Cancer Cell; 2008 Jun; 13(6):519-28. PubMed ID: 18538735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey.
    Smith SC; Palanisamy N; Zuhlke KA; Johnson AM; Siddiqui J; Chinnaiyan AM; Kunju LP; Cooney KA; Tomlins SA
    Am J Surg Pathol; 2014 May; 38(5):615-26. PubMed ID: 24722062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for molecular differences in prostate cancer between African American and Caucasian men.
    Khani F; Mosquera JM; Park K; Blattner M; O'Reilly C; MacDonald TY; Chen Z; Srivastava A; Tewari AK; Barbieri CE; Rubin MA; Robinson BD
    Clin Cancer Res; 2014 Sep; 20(18):4925-34. PubMed ID: 25056375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct genomic aberrations associated with ERG rearranged prostate cancer.
    Demichelis F; Setlur SR; Beroukhim R; Perner S; Korbel JO; Lafargue CJ; Pflueger D; Pina C; Hofer MD; Sboner A; Svensson MA; Rickman DS; Urban A; Snyder M; Meyerson M; Lee C; Gerstein MB; Kuefer R; Rubin MA
    Genes Chromosomes Cancer; 2009 Apr; 48(4):366-80. PubMed ID: 19156837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry.
    Fontugne J; Davis K; Palanisamy N; Udager A; Mehra R; McDaniel AS; Siddiqui J; Rubin MA; Mosquera JM; Tomlins SA
    Mod Pathol; 2016 Feb; 29(2):157-65. PubMed ID: 26743468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
    Pflueger D; Rickman DS; Sboner A; Perner S; LaFargue CJ; Svensson MA; Moss BJ; Kitabayashi N; Pan Y; de la Taille A; Kuefer R; Tewari AK; Demichelis F; Chee MS; Gerstein MB; Rubin MA
    Neoplasia; 2009 Aug; 11(8):804-11. PubMed ID: 19649210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.
    Tomlins SA; Palanisamy N; Siddiqui J; Chinnaiyan AM; Kunju LP
    Arch Pathol Lab Med; 2012 Aug; 136(8):935-46. PubMed ID: 22849743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.